Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2016-011

Bond Abbreviation: 13 Peak 01 Bond Code: 122227

Bond Abbreviation: 13 Peak 02 Bond Code: 122344

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Related Party Transactions of Capital Increase in Jianfeng Pharmaceutical

Overview of 1. Related Party Transactions

(I) On April 5, 2016 , the board of directors of Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a holding subsidiary of the Company, made a resolution, it is proposed to use the audited consolidated statement at the end of 2015 attributable to the owner of the parent company equity 30137.64 yuan as the basis for the monetary capital increase, the total amount of this capital increase is 100 million yuan. The Company holds a 99.16 equity interest in Peak Pharmaceuticals, and the amount of capital increase enjoyed by the Company is $99.16 million. Jinhua Tongji State-owned Assets Investment Co., Ltd. (hereinafter referred to as "Tongji State Investment") holds a 0.84 per cent stake in Jianfeng Pharmaceutical, and the amount of capital increase enjoyed by Tongji State Investment is 840000 yuan.

(II) Tongji Guotou holds 16.15 equity of the company and is the controlling shareholder of the company. Mr. Jiang Xiaomeng, chairman of the company, is also a director of Tongji Guotou. According to the relevant provisions of the Shanghai Stock Exchange Stock Listing Rules, Tongji Guotou is a related legal person of the company, and joint investment with related parties is a related transaction.

(III) the amount of this related party transaction is 9916 yuan, exceeding 30 million yuan, but it does not reach 5% of the absolute value of the company's audited net assets in 2015. this related transactions do not constitute a major asset restructuring of the listing Corporation's major asset restructuring management approach.

2. Related Party Introduction

1 , Name: Jinhua Tongji State-owned Assets Investment Co., Ltd.

2 , Nature of Enterprise: Limited Liability Company (Wholly State-owned)

3 , Place of Registration: no. 64 4

, 1st floor, No. 1389 Danxi Road, Jinhua City, Zhejiang Province, main office location: No. 69

5 , 1st floor, No. 1389 Danxi Road, Jinhua City, Zhejiang Province, legal representative: Liu Bo

6 , registered capital: RMB 9500 Yuan

7 , main business: general business items: authorized investment and operation of state-owned assets.

8 , Main Financial Indicators of Related Persons in Recent Year

As of December 31, 2015 , Tongji Guotou had total assets of 358.7316 million yuan, net assets of 342.4002 million yuan and net profit of 14.8026 million yuan.

Basic Information of 3. Jianfeng Pharmaceutical

, Basic Information of Transaction Target

(1 ) Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.

(2 ) Enterprise Nature: Limited Liability Company

(3 ) Registration Place: main office location of

(4 ) on the second floor of X02 office quality inspection building, No. 58 Gaofan section, Baitang downline, Wucheng district, Jinhua city, Zhejiang province:

(5 ) on the fourth-fifth floor of Jianfeng building, No. 88 Wujiang east road, Jinhua city, Zhejiang province legal representative: Jiang Xiaomeng

(6 120) registered capital: RMB 149.07 million yuan

(7

) main business: drug research and development and production (operating with valid license); Import of raw and auxiliary materials for production and scientific research; Imported mechanical equipment, instruments and spare parts. (For projects subject to approval according to law, business activities can only be carried out after approval by relevant departments)

2

, main financial data of the transaction target (unit: ten thousand yuan)

subject 2015 The above financial indicators have been audited by Tianjian Certified Public Accountants, which is qualified to practice securities.

2015 # December 31, 142	total assets
104765.48	total liabilities
70945.02	Ownership of Parent Company Owner's Equity
30137.64	Asset-Liability Ratio
67.72%
Year	Operating Income
113292.85	Net Profit Attributable to Owner of Parent Company
5924.42

Main Contents of 4. Related Party Transactions

Principles and Methods for Price Determination of (I) Related Party Transactions

This capital increase is to be based on the owner's equity attributable to the parent company after the annual audit of Jianfeng Pharmaceutical 2015 .

(II)'s total capital increase this time is 10,000

.49 million yuan, and the company enjoys the capital increase right of 99.16 million yuan according to its shareholding ratio. Tongji Guotou enjoys the capital increase right of 840000 yuan according to its shareholding ratio. If both parties are fully funded, after the completion of the capital increase, the registered capital of Jianfeng Pharmaceutical will increase to 198.53 million yuan, of which Jianfeng Pharmaceutical will account for 99.16 percent and Tongji Guotou will account for 0.84 percent.

The amount of capital increase subscribed by the (III) capital increase party shall be remitted to Jianfeng Pharmaceutical's account before June 30, 2016

.

5. the purpose of the related party transaction and its impact on the listed company

Jianfeng Pharmaceutical is a controlling subsidiary of the company, and its pharmaceutical business is one of the company's two main businesses. With the continuous expansion of the development scale, the demand for funds is also increasing, especially after the investment of Jinxi project, the debt ratio of Jianfeng Pharmaceutical is on the high side, the capital increase of Jianfeng Pharmaceutical will help improve its asset structure, enhance its strength and competitiveness, and will contribute to the healthy and sustainable development of the company's pharmaceutical industry.

6. the review procedure to be performed for the related party transaction

On April 8, 266, 2016 , the company held the 6th meeting of the 9th board of directors, and all eight directors of the company attended the meeting in person. Mr. Jiang Xiaomeng, the related director, avoided voting on the proposal, which is in line with the relevant provisions of the Company Law and the Articles of Association of the company, the resolutions made are legal and valid. After deliberation and voting, the board of directors deliberated and passed the "related party transaction proposal on capital increase of Jianfeng pharmaceutical" with 7 votes in favor, 0 against and 0 abstention. It was agreed that the company would invest 99.16 million yuan to increase the capital of Peak Pharmaceuticals.

The amount of this related party transaction has not reached 5% of the absolute value of the audited net assets of the company in 2015

. According to the company's "Articles of Association", it does not need to be submitted to the general meeting of shareholders for approval. Before

the board of directors, the company reported to the independent directors, and the independent directors made a prior approval statement, believing that the capital increase price of the related party transaction was determined on the basis of the audited net assets and enjoyed the capital increase right according to the shareholding ratio of each shareholder, and that the company could ensure that its share of equity would not be reduced after participating in the capital increase. After the implementation of the related party transaction, it will effectively optimize the asset structure of the invested company, enhance the strength of the enterprise, enhance the competitiveness, and ensure the sustainable and healthy development of the enterprise. The above related party transactions did not harm the interests of the company and shareholders, and agreed to submit the proposal to the 6th 275 meeting of the ninth board of directors of the company for deliberation. The independent directors expressed their independent opinions on the resolution made by the board of directors, and believed that the formation of the resolution complied with the "Company Law", the "Articles of Association" and other relevant provisions, and did not harm the interests of small and medium shareholders.

The audit committee of the company's board of directors issued a written review opinion on the related transaction, and believed that the relevant information on the related transaction was complete and the company's management had conducted comprehensive communication with it. The related party transaction belongs to the normal economic behavior of the company and meets the needs of the company's operation and development; the price of capital increase is determined according to the audited net assets, and the capital increase right is enjoyed according to the shareholding ratio of each shareholder. After the capital increase, the company's equity share of the invested unit will not decline; the transaction follows the principles of fairness, impartiality, voluntariness and good faith, and does not harm the interests of the company and shareholders.

Tongji Company's participation in this capital increase still needs to be approved by its competent authorities and departments.

6. Online Announcement Annex

(I) Statement Approved in advance by Independent Directors

(II) Independent Director Opinion Signed and Confirmed by Independent Directors

(III) Written Review Opinion of Audit Committee of Board of Directors on Related Party Transactions

Financial Statements and Audit Report of (IV) Jianfeng Pharmaceutical

hereby announce

April 12, 2016